IMU

6.82%

4.1¢ imugene limited

Ann: FDA IND APPROVAL FOR ONCOLYTIC VIROTHERAPY VAXINIA, page-36

First 36 Last

Share
Profile

Follow
Steini

12,920 Posts.

3954

13/12/21

12:59

Post #: 58255720
Share

Originally posted by PilbaraBoy: ↑

You'd think so right plovagurl????

But remember - this is the pathetic farce known as the ASX that we are dealing with (as well as imbecile so called "investors" that barely understand what Telstra & Woolworths do, let alone a biotech company researching cutting-edge cancer immuno-oncology therapies.)

Let me recap: In just the past 4 weeks Imugene has:

* Announced a Clinical Trial Agreement with Merck & Pfizer.
* Obtained S&P admittance into the ASX200.
* Received $6 million in cash (via conversion of 150 million IMUOB options).
* Received FDA IND approval for its second Oncolytic Virus (Vaxinia).
* Received FDA IND approval for an additional Phase 2 clinical trial for HER-Vaxx

Any other biotech company, on any other index in the world (with a comparable share price & market cap to Imugene) would have seen it's share price hit $1.00 as result of all this cumulative news.

Only 1 in 10,000 drug applications receives an FDA IND approval. For Imugene to receive 2 in a single day is truly remarkable.

But here, on this joke known as the "ASX", sitting now at a share price of 52 cents, we are actually 12% BELOW the 59 cents we were at before we received the first monumental news of the Merck & Pfizer agreement???????????

How the hell is that possible?

Are the pathetic leaches trading their shares to make a measley2 cents profit responsible? No, those cretins don't have that much sway in the market. So that must mean that it's institutional/broker driven games that are reducing & capping the share price.

Whatmighthaveben probably hit the nail on the head when he wrote on the weekend that it was coming time for Imugene to leave the ASX and list on the NASDAQ. A company like Imugene with it's priceless IP, current cash reserves of AUD$120 million, and huge pipeline of FDA-approved drug candidates - would be worth at least USD$10 Billion (AUD$14 Billion) ... or AUD$2.30 a share.

Congratulations to Leslie, Paul and the tireless IMU team for today's incredibly amazing news.

Expand

PB, even more to say that ALL 5 of IMU's 5 IND application went through first time. Not sure if any other ASX listed or even world wide listed company got a 100% IND approval track record.

Well done Team IMU, what a journey over the past 5-6 years and what a journey still to come.

PB, the sp will end up where it belongs, doesn't matter whether today or another day.

GLTA

IMU Price at posting: 52.5¢ Sentiment: Buy Disclosure: Held
55 Upvote

0 Great analysis

Reply

Top Stories

EEG

NT Gov't delivers environmental approval for Empire Energy's Beetaloo Carpentaria pilot gas play

BTH

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

GDM

Banshee's historic trenches prove rich in antimony and gold for GDM

Week 46 Wrap: Copper hits 2mth low as Trump threatens net zero pace; US rally fades; HotCopper’s picks

HotCopper Highlights: Your most watched stocks for Week 46, 2024

CUF

CuFe sells its Crossroads gold royalty to Northern Star for $4M cash; says better than waiting for mine launch

CLE

Cyclone signs MOU with Vale for development of Iron Bear play

BNL

Blue Star Helium sees approval for five more wells at 'Galactica/Pegasus' project in Colorado

3DA

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

IRX

InhaleRX gains approval for clinical trial to test non-opioid therapy for cancer pain

First 36 Last

Add IMU (ASX) to my watchlist

(20min delay)
Last 4.1¢		Change -0.003(6.82%)		Mkt cap ! $304.9M

Open	High	Low	Value	Volume
4.3¢	4.4¢	4.1¢	$1.607M	38.52M

Buyers (Bids)

No.	Vol.	Price($)
23	4542680	4.1¢

Sellers (Offers)

Price($)	Vol.	No.
4.3¢	1675759	9

View Market Depth

No.	Vol.	Price($)
15	2598776	0.041
76	6281075	0.040
31	5664241	0.039
15	2789416	0.038
10	1400513	0.037

Price($)	Vol.	No.
0.043	1652096	8
0.044	1145733	8
0.045	1715026	12
0.046	1642231	7
0.047	1652765	8

Last trade - 16.10pm 15/11/2024 (20 minute delay)

IMU (ASX) Chart

Ann: FDA IND APPROVAL FOR ONCOLYTIC VIROTHERAPY VAXINIA, page-36

NT Gov't delivers environmental approval for Empire Energy's Beetaloo Carpentaria pilot gas play

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

Banshee's historic trenches prove rich in antimony and gold for GDM

Week 46 Wrap: Copper hits 2mth low as Trump threatens net zero pace; US rally fades; HotCopper’s picks

HotCopper Highlights: Your most watched stocks for Week 46, 2024

CuFe sells its Crossroads gold royalty to Northern Star for $4M cash; says better than waiting for mine launch

Cyclone signs MOU with Vale for development of Iron Bear play

Blue Star Helium sees approval for five more wells at 'Galactica/Pegasus' project in Colorado

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

InhaleRX gains approval for clinical trial to test non-opioid therapy for cancer pain

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: FDA IND APPROVAL FOR ONCOLYTIC VIROTHERAPY VAXINIA, page-36

Top Stories

NT Gov't delivers environmental approval for Empire Energy's Beetaloo Carpentaria pilot gas play

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

Banshee's historic trenches prove rich in antimony and gold for GDM

Week 46 Wrap: Copper hits 2mth low as Trump threatens net zero pace; US rally fades; HotCopper’s picks

HotCopper Highlights: Your most watched stocks for Week 46, 2024

CuFe sells its Crossroads gold royalty to Northern Star for $4M cash; says better than waiting for mine launch

Cyclone signs MOU with Vale for development of Iron Bear play

Blue Star Helium sees approval for five more wells at 'Galactica/Pegasus' project in Colorado

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

InhaleRX gains approval for clinical trial to test non-opioid therapy for cancer pain

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News